Qrons (QRON) Treasury Stock : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Qrons Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Qrons's treasury stock for the quarter that ended in Mar. 2024 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Qrons Treasury Stock Historical Data

The historical data trend for Qrons's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qrons Treasury Stock Chart

Qrons Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Treasury Stock

Get a 7-Day Free Trial

Qrons Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Treasury Stock	Get a 7-Day Free Trial															-	-	-	-	-

Qrons Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Qrons (QRON) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qrons Inc (OTCPK:QRON) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

28-10 Jackson Avenue, No. 26N, Long Island City, New York, NY, USA, 11101

Website

https://www.qrons.com

Qrons Inc is a biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries. The technology would treat a wide range of neurodegenerative diseases. The treatment integrates proprietary, engineered mesenchymal stem cells, 3D printable scaffolding, smart materials, and a novel delivery system. The firm has two product candidates, QS100TM for treating penetrating brain injuries and QS200TM, for treating concussions and other diffused axonal injuries.

Executives

John N Bonfiglio	officer: Chief Operating Officer	C/O MICROLIN BIO, INC., NEW YORK NY 10022
Jonah Meer	director, 10 percent owner, officer: CEO, CFO and Secretary	28-10 JACKSON AVENUE, #26N, LONG ISLAND CITY NY 11101
Ido Merfeld	director, 10 percent owner, officer: President	153 HAGILBOA STREET, NIRIT L3 44805